Olema Pharmaceuticals Inc... (OLMA)
Olema Pharmaceuticals Inc. (OLMA) Stock Price, Analysis & Data
| Precio de compra | 8.05 |
| Capitalización de mercado | 989.6M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -204.57M |
| Beta | 2.01 |
| EPS (TTM) | -2.12 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -4.21 |
| P/B (TTM) | 2.30 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 9, 2026 |
| Precio de venta | 13.88 |
| Volumen | 1,321,752 |
| Volumen medio (20D) | 1,424,543 |
| Abierto | 10.90 |
| Anterior Cerrar | 10.65 |
| Rango del día | 10.77 - 11.32 |
| Rango de 52 semanas | 5.34 - 36.26 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...
Desempeño financiero
En 2025, los ingresos de Olema Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -162.45M, un aumento de 25.47%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 meses hace · Simply Wall St.
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation GapOlema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tu...
